Swiss Cardio Technologies

Swiss Cardio Technologies AG is a spin-off from the University of Berne, Switzerland and was founded by a group of cardiovascular surgery specialists in 2008.

The company has been developing the cardioplegic solution Cardioplexol® with marketing approvals in 10 EU countries and Switzerland.

Product

Swiss Cardio Technologies is the exclusive global license holder of Cardioplexol®. A novel standardized ultra-low-volume cardioplegic solution. More information can be found here.

Cardioplexol® is marketed by:

Medius AG, Neue Bahnhofstrasse 160, 4132 Muttenz, Switzerland (Switzerland)

MIT Gesundheit GmbH, Thaerstrasse 4A, 47533 Kleve, Germany (Europe)

News

News update coming shortly.

Team

We are an experienced team of medical professionals, industrial pharmacists and business management.

Marc Froehlich

Management, Program Lead

Marc Froehlich

Management, Program Lead

Marc Froehlich

Management, Program Lead

Dr. Erich Gygax

Perfusionist, Product Lead

Dr. Erich Gygax

Perfusionist, Product Lead

Dr. Erich Gygax

Perfusionist, Product Lead

Dr. Andreas Brutsche

Pharmacist, Project Manager

Dr. Andreas Brutsche

Pharmacist, Project Manager

Dr. Andreas Brutsche

Pharmacist, Project Manager

Dr. Neil Judge

Chemist, Project Manager

Dr. Neil Judge

Chemist, Project Manager

Dr. Neil Judge

Chemist, Project Manager

Gregor Felder

CFO

Gregor Felder

CFO

Gregor Felder

CFO

Governing Board

Strategic lead, control and advisory body of experienced executives and experts that support management in long-term strategic decisions, market opportunities, innovation initiatives, and risk assessment.